Able Laboratories ( ABRX) said the Food and Drug Administration approved the company's abbreviated new drug application for a generic version of Lortab, a treatment for moderate to moderately severe pain.

Word that the agency had approved the formulation, consisting of hydrocodone bitartrate and acetaminophen tablets, lifted shares of Able $1.29, or 8%, to $17.55.

Since March 2001, Able, a maker of generic pharmaceuticals, has received 29 abbreviated new drug application approvals. The total market for Able's newly approved drug is estimated at about $230 million, the company said in a press release.

More from Technology

Elon Musk's Latest Twitter Tirade Is the Dumbest Thing on Wall Street

Elon Musk's Latest Twitter Tirade Is the Dumbest Thing on Wall Street

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Some Companies Are Already Feeling the Effect of GDPR

Some Companies Are Already Feeling the Effect of GDPR

Experts Break Down GDPR Risks for Investors

Experts Break Down GDPR Risks for Investors

Netflix Ready to Surpass Disney as America's Most Valuable Media Company

Netflix Ready to Surpass Disney as America's Most Valuable Media Company